[1] Björnsson ES, Bergmann OM, Björnsson HK, et al. Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland. Gastroenterology, 2013, 144: 1419-1425.
[2] Shen T,Liu Y, Shang J, et al. Incidence and Etiology of Drug-Induced Liver Injury in Mainland China. Gastroenterology,2019,156:2230-2241.e11.
[3] Devarbhavi H, Aithal G, Treeprasertsuk S, et al. Drug-induced liver injury: Asia Pacific Association of Study of Liver consensus guidelines. Hepatol Int,2021,15:258-282.
[4] Chalasani NP, Maddur H, Russo MW, et al. ACG Clinical Guideline: Diagnosis and Management of Idiosyncratic Drug-Induced Liver Injury. Am J Gastroenterol, 2021, 116:878-898.
[5] Danan G, Teschke R. RUCAM in drug and herb induced liver injury: The update. Int J Mol Sci, 2016, 17:14-46.
[6] Yu YC, Mao YM, Chen CW, et al. CSH Guideline for the Diagnosis and Treatment of Drug-induced Liver Injury. Hepatol Int, 2017, 11: 221-241.
[7] Li C, Rao T, Chen X, et al. HLA-B*35:01 Allele is a potential biomarker for predicting polygonum multiflorum-induced liver injury in humans, Hepatology, 2019,70:346-357.
[8] Wang Z, Li W, Jing H, et al.Generation of hepatic spheroids using human hepatocyte-derived liver progenitor-like cells for hepatotoxicity screening. Theranostics,2019,9:6690-6705.
[9] Chen Y, Tang D, Wu H, et al. Assessment of long-term functional maintenance of primary human hepatocytes to predict drug-induced hepatoxicity in vitro. Arch Toxicol, 2021,95:2431-2442.
[10] 于乐成, 陈成伟. 药物性肝损伤的发生机制: 当前认识和未来需求. 临床肝胆病杂志, 2021, 37: 229-239. |
